Trimetrexate is a parenterally administered folate antagonist that is used as a second line therapy for severe Pneumocystis jirovecii (previously carinii) pneumonia. Trimetrexate therapy has been associated with transient, mild serum enzyme elevations during therapy, but has not been convincingly linked to instances of acute, clinically apparent liver injury. It is grouped under the following drug class(es): Antineoplastic agents. Its therapeutic use is listed as antiparasitics and antiprotozoals. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Trimexate and Trimetrexatum. Its PubChem CID is 5583.
Trimetrexate
| CAS No | 52128-35-5 |
|---|---|
| Molecular Formula | C19H23N5O3 |
| Molecular Weight | 369.4 g/mol |
| Synonyms | 5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline-2,4-diamine |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Trimetrexate is a parenterally administered folate antagonist that is used as a second line therapy for severe Pneumocystis jirovecii (previously carinii) pneumonia.
The listed CAS number is 52128-35-5.
The listed molecular formula is C19H23N5O3.
The listed molecular weight is 369.4 g/mol.
5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline-2,4-diamine.
The source lists Trimexate and Trimetrexatum.